| Type 2 Diabetes Mellitus |
1 |
1 |
| Prediabetes |
0 |
0.75 |
| Hemoglobin |
0 |
0.49 |
| Obesity |
0 |
0.48 |
| Body Mass Index |
0 |
0.2 |
| Blood |
0 |
0.14 |
| Exercise |
0 |
0.14 |
| Insulin Resistance |
0 |
0.14 |
| Preventive Screening |
0 |
0.14 |
| Weight Management |
0 |
0.13 |
| Blood Transfusion |
0 |
0.12 |
| Weight Loss |
0 |
0.12 |
| Pregnancy |
0 |
0.11 |
| Renal Failure |
0 |
0.1 |
| Diabetes Mellitus |
0 |
0.09 |
| Diet |
0 |
0.09 |
| Plasma |
0 |
0.09 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Hemodialysis |
0 |
0.07 |
| Clinical Research |
0 |
0.06 |
| Epidemic |
0 |
0.06 |
| Nutrition |
0 |
0.06 |
| Tolerance |
0 |
0.06 |
| Lactic Acidosis |
0 |
0.04 |
| Acidosis |
0 |
0.03 |
| Blindness |
0 |
0.03 |
| Centers for Disease Control and Prevention |
0 |
0.03 |
| Cerebrovascular Accident |
0 |
0.03 |
| Concerns of Elderly |
0 |
0.03 |
| DPP-4 Inhibitors |
0 |
0.03 |
| Endocrinology |
0 |
0.03 |
| Erythropoietin |
0 |
0.03 |
| Geriatrics |
0 |
0.03 |
| Gestational Diabetes Mellitus |
0 |
0.03 |
| Heart |
0 |
0.03 |
| Infarction |
0 |
0.03 |
| Meta-Analysis |
0 |
0.03 |
| Myocardial Infarction (MI) |
0 |
0.03 |
| Neuropathy |
0 |
0.03 |
| Orbit |
0 |
0.03 |
| Peripheral Artery Disease |
0 |
0.03 |
| Primary Care |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Retinal Diseases |
0 |
0.03 |
| Retinopathy |
0 |
0.03 |
| SGLT2 Inhibitor |
0 |
0.03 |
| Sickle Cell Anemia |
0 |
0.03 |
| Sulfonylureas |
0 |
0.03 |
| Transfusion |
0 |
0.03 |
| Young Adult |
0 |
0.03 |